Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : ImClone Systems Incorporated
Femme et Homme Max 99 ans
ImClone Systems Incorporated
MAJ Il y a 4 ans
Estudio de fase 2, multicéntrico, en abierto, para evaluar la seguridad y la eficacia del IMC-1121B en combinación con 5-FU/AF y oxaliplatino (FOLFOX-6 modificado) como tratamiento de primera línea en pacientes con cáncer colorrectal metastásico". "An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination with 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients with Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the progression-free survival (PFS) in patients with metastatic colorectal cancer when treated with the monoclonal antibody IMC-1121B in combination ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
ImClone Systems Incorporated
MAJ Il y a 4 ans
Estudio de cinco niveles, de fase 2, abierto, de IMC-A12 administrado como único producto cada 2 semanas a pacientes con sarcoma de Ewing/TNEPP y sarcoma de tejido blando tratado anteriormente, avanzado o metastásico. A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET
To determine the progression-free survival (PFS) rate assessed 12 weeks after the initiation of IMC-A12 monotherapy, administered every 2 weeks to patients with previously-treated, advanced or metasta...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
ImClone Systems Incorporated
MAJ Il y a 4 ans
Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma
The primary objective is to determine the progression-free survival (PFS) of patients with metastatic malignant melanoma who have not received prior chemotherapy for metastatic disease when treated wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations